YTHDF1 and irritable bowel syndrome: As a treatment for irritable bowel syndrome with constipation, compound 48 (Tegaserod, YTHDF1 IC50 = 13.82 μM) (Fig. 13B) was recently reported as a novel potential YTHDF1 inhibitor, which prevents YTHDF1 from binding m6A modified mRNA and YTHDF1 dependent protein translation.